EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rivaroxaban Counteracts the Adverse Effects of Warfarin on Plaque Vulnerability and Vessel Wall Remodelling

Anxhela Habibi, Vanessa Broker, Juliana H Boukhaled, Dani Veldhuis, Jenny Surholt, Peter Leenders, Cecile Maassen, Magdolna Nagy iD, Henri M H Spronk, Wolfram Ruf, Leon J Schurgers iD, Armand M G Jaminon

TH Open · 21.10.2026 · 10 (CP)

DOI: 10.1055/a-2979-1901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift TH Open, erschienen am 21.10.2026. Verfasst von Anxhela Habibi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of BiochemistryCardiovascular Research Institute Maastricht, Maastricht UniversityMaastrichtLimburgThe Netherlands. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pharmaceuticals Bayer, Dutch Heart Foundation, Trombosestichting Nederland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis is a major cause of cardiovascular diseases (CVDs) globally, characterized by vascular calcification (VC), increasing the risk of myocardial infarction and stroke. Oral anticoagulants are widely prescribed to prevent recurrent thrombotic events. However, increasing concern surrounds warfarin, whose unfavorable pharmacokinetic profile and interference with vitamin K-dependent pathways have been implicated in VC. Rivaroxaban represents an alternative anticoagulant, yet its ability to mitigate warfarin-induced vascular injury remains insufficiently defined. This study investigated whether switching from warfarin to rivaroxaban benefits plaque progression and might hold progression of calcification. Apolipoprotein E-deficient (Apoe−/− ) mice were fed a Western-type diet (WTD) for 18 weeks, supplemented without (control) or with either warfarin or rivaroxaban. An additional group received warfarin for 6 weeks, after which they switched to rivaroxaban for 12 weeks. Plaque size was comparable in both the continuous rivaroxaban group and the switching group and was decreased compared with 18 weeks in both the warfarin and control groups. Notably, VC was decreased in both rivaroxaban groups, with a more significant decrease observed in the switching group compared with continuous warfarin treatment. The switching group showed better vascular integrity with lower vascular stiffness and fewer elastic fiber breaks. Additionally, the switching group showed features of a more stable plaque phenotype with increased α-smooth muscle actin (αSMA)-positive vascular smooth muscle cells and a higher collagen content. Interestingly, all three anticoagulation therapies showed decreased expression of protease-activated receptor 2 (PAR2) together with a decrease in oxidative stress in the plaques. However, only rivaroxaban treatments showed reduced matrix metalloproteinase 9 (MMP-9) expression in plaques compared with both control and warfarin groups. Our results suggest that rivaroxaban ameliorates the adverse effects of warfarin, offering significant benefits on atherosclerotic burden and plaque stability. Transitioning from warfarin to rivaroxaban has the potential to reshape clinical practice by offering anticoagulation and reducing the practical limitations associated with vitamin K antagonists, particularly in patients with coexisting CVDs.

Schlagwörter

Stichwörter der Autor:innen

atherosclerosisoral anticoagulantsplaque stabilityrivaroxabanvascular calcificationwarfarin

Autor:innen und Institutionen

  • Department of BiochemistryCardiovascular Research Institute Maastricht, Maastricht UniversityMaastrichtLimburgThe Netherlands.
  • Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University MainzMainzRhineland-PalatinateGermany.
  • Department of NephrologyUniversity of MontpellierMontpellierOccitanieFrance.
  • Thrombosis Expertise Center, Heart and Vascular Center, Maastricht University Medical Centre+MaastrichtLimburgThe Netherlands.

ORCID-Profile: Magdolna Nagy, Leon J Schurgers

Förderung

  • Pharmaceuticals Bayer
  • Dutch Heart Foundation
  • Trombosestichting Nederland
  • Marie Skłodowska-Curie Actions

Zitieren

APA

Habibi, A., Broker, V., Boukhaled, J. H., Veldhuis, D., Surholt, J., Leenders, P., Maassen, C., Nagy, M., Spronk, H. M. H., Ruf, W., Schurgers, L. J., & Jaminon, A. M. G. (2026). Rivaroxaban Counteracts the Adverse Effects of Warfarin on Plaque Vulnerability and Vessel Wall Remodelling. TH Open, 10(CP). https://doi.org/10.1055/a-2979-1901

Vancouver

Habibi A, Broker V, Boukhaled JH, Veldhuis D, Surholt J, Leenders P, et al. Rivaroxaban Counteracts the Adverse Effects of Warfarin on Plaque Vulnerability and Vessel Wall Remodelling. TH Open. 2026;10(CP). doi:10.1055/a-2979-1901

BibTeX
@article{Habibi2026,
  author = {Habibi, Anxhela and Broker, Vanessa and Boukhaled, Juliana H and Veldhuis, Dani and Surholt, Jenny and Leenders, Peter and Maassen, Cecile and Nagy, Magdolna and Spronk, Henri M H and Ruf, Wolfram and Schurgers, Leon J and Jaminon, Armand M G},
  title = {Rivaroxaban Counteracts the Adverse Effects of Warfarin on Plaque Vulnerability and Vessel Wall Remodelling},
  journal = {TH Open},
  year = {2026},
  volume = {10},
  number = {CP},
  doi = {10.1055/a-2979-1901}
}
Kostenlos starten →